Recordati S.p.A. stock (IT0003828271): shares trade steadily in Milan as investors weigh pending CVC go-private offer

Recordati S.p.A. shares on Borsa Italiana in Italy were little moved this week, with the stock changing hands around the low-50 EUR area while investors continue to evaluate the implications of a sizeable go-private proposal led by CVC and Groupe Bruxelles Lambert.

The pharmaceutical group’s ordinary shares, which are part of the FTSE MIB index in Milan, closed at EUR 51.50 on 05/30/2026, up EUR 0.68 on the day, according to price data published by Borsa Italiana.

This pricing level keeps Recordati broadly in the middle of its trading range for the year to date and comes as the Italian specialty drug maker remains the subject of an agreed acquisition proposal from private equity firm CVC Capital Partners and its co-investor Groupe Bruxelles Lambert, valuing the company’s equity at roughly EUR 10.7 billion when the offer was announced.

The company, headquartered in Italy and listed on Borsa Italiana, has been in focus among domestic investors since CVC first moved to secure control, a deal structure that has been followed closely by the local financial community because Recordati is a long-standing Italian healthcare champion.

While the stock price in recent sessions has reflected expectations around the pending transaction and the cash offer terms, trading volumes on the home market have remained orderly and the shares continue to be included in the country’s flagship FTSE MIB benchmark, meaning institutional investors tracking the index still have to hold the name as long as it is part of the basket.

The stock traded at 51.50 EUR on 05/30/2026 on Borsa Italiana, according to Borsa Italiana price information as of the same date, suggesting that markets are discounting a high probability of completion of the announced go-private deal but are still attentive to regulatory and procedural milestones that are customary in such transactions.

Italian regulators and competition authorities have been monitoring the process, which is typical for large domestic transactions in strategic sectors like pharmaceuticals, yet to date there has been no official communication indicating that the deal has closed and the listing has been terminated, so Recordati continues to trade as a regular component of the Milan market.

For investors in the euro area, Recordati’s primary liquidity remains in Milan, but the stock is also accessible through German trading venues such as Tradegate, where it is quoted in EUR for cross-border retail investors seeking exposure to the Italian healthcare sector through locally settled trading channels.

As the market digests the combination of the acquisition proposal and the company’s fundamental performance, the share price has tended to oscillate within a relatively narrow band around the implied offer valuation, a pattern that is typical when a binding take-private bid sets a reference value against which arbitrage-oriented investors position themselves.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Recordati S.p.A.: core business model

Recordati focuses on developing, manufacturing and marketing prescription and rare disease medicines, with a portfolio weighted toward specialty therapeutics that generate revenue through proprietary brands across Europe and other international markets.

Insider activity and ownership structure

Since the announcement of the go-private offer by CVC and Groupe Bruxelles Lambert, the ownership profile of Recordati has been characterized by a growing role for private equity sponsors and their investment vehicles, alongside a still meaningful free float that trades on Borsa Italiana while the transaction remains pending.

Public filings and transaction documentation around the offer describe a structure in which the bidding consortium aims to acquire control of the company through a cash offer, which would, once fully executed and approved, consolidate a majority stake with the private equity buyers and potentially lead to a squeeze-out of remaining minority shareholders and a subsequent delisting from the Milan exchange, subject to the completion of all required steps.

Conclusion

Recordati’s relatively stable share price near EUR 51.50 on Borsa Italiana underscores how the Italian market is largely trading the stock as a transaction-driven situation anchored by the pending CVC-led go-private offer.

At the same time, the evolving ownership structure, with private equity sponsors seeking control, highlights how future governance and capital allocation at the company could change once the takeover is completed, a factor that investors closely tracking the healthcare sector will continue to watch.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.